帕利哌酮缓释片联合奥氮平治疗精神分裂症的疗效及安全性研究

Clinical efficacy and safety of Paliperidone Extended-Release Tablets combined with Olanzapine in schizophrenia

目的探讨帕利哌酮缓释片联合奥氮平治疗精神分裂症的疗效及安全性。方法选取2014年5月至2015年5月于我院收治的精神分裂症患者60例。采用随机数表法分为对照组和观察组,每组30例。对照组患者仅使用奥氮平治疗,观察组患者在对照组治疗的基础上联合使用帕利哌酮缓释片治疗,疗程均为8周,观察并比较两组患者的治疗效果、阳性和阴性症状量表(PANSS)评分、简明精神病评定量表(BPRS)评分及安全性。结果经过8周的治疗,观察组患者的治疗总有效率为96.67%(29/30),明显高于对照组的86.67%(26/30),差异有统计学意义(P<0.05);治疗后第2、4、6、8周末,观察组患者的PANSS评分和BPRS评分均明显低于对照组,差异均有统计学意义(P<0.05);观察组患者的不良反应总发生率为73.33%(22/30),略高于对照组的66.67%(20/30),但两组间比较差异无统计学意义(P>0.05)。结论帕利哌酮缓释片联合奥氮平治疗精神分裂症的临床效果优于仅使用奥氮平治疗,且安全性与单独使用奥氮平治疗无差异,值得在临床上推广使用。

Objective To investigate the efficacy and safety of Paliperidone Extended-Release Tablets combined with Olanzapine in the treatment of schizophrenia. Methods Sixty patients of schizophrenia who were treated in our hospital from May 2014 to May 2015 were selected as the subjects of this study. According to a random number table, the patients were divided into control group and observation group, with 30 cases in each group. The control group was treated with Olanzapine, and the observation group applied Paliperidone Extended-Release Tablets combined with Olanzapine, for 8 weeks. The therapeutic effect, Positive and Negative Syndrome Scale(PANSS) score, Brief Psychiatric Rating Scale(BPRS) score and safety were observed. Results After 8 weeks of treatment, the total effective rate of the observation group was 96.67%(29/30), significantly higher than 86.67%(26/30) in the control group(P<0.05). After treatment for 2 weeks, 4 weeks, 6 weeks and 8 weeks, PANSS and BPRS scores in the observation group were significantly lower than those of the control group, with statistically significant differences(P<0.05). The incidence of adverse reactions in the observation group was 73.33%(22/30), slightly higher than that of the control group of 66.67%(20/30),but the difference was not statistically significant(P>0.05). Conclusion Paliperidone Extended-Release Tablets combined with Olanzapine has better clinical efficacy than Olanzapine for the treatment of schizophrenia, with similar safety,which should be recommended in clinical practice.